Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
A gene therapy protects eye cells in mice with a rare disorder that causes vision loss, especially when used in combination with other gene therapies, shows a study published in eLife.
LambdaVision, the Farmington, Connecticut-based biotech firm that developed the artificial retina, is exploring optimizing production of an artificial retina in space, in a series of missions to the International Space Station.
New research from the University of Utah provides insight on how people with retinal degenerative disease can maintain their night vision for a relatively long period of time.
Researchers from the University of Buffalo have found new information about retinitis pigmentosa, a condition that begins in childhood with night blindness and loss of peripheral vision.
Researchers who made a knock-in mouse-model of the genetic disorder retinitis pigmentosa 59, or RP59, found no retinal degeneration or thinning, calling into question the commonly accepted mechanism for RP59.
Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes.
Millions of Americans are progressively losing their sight as cells in their eyes deteriorate, but a new therapy developed by researchers at the University of California, Berkeley, could help prolong useful vision and delay total blindness.
Researchers at the University of New Hampshire have reported the first structural model for a key enzyme, and its activating protein, that can play a role in some genetically inherited eye diseases like retinitis pigmentosa and night blindness.
